


**Product Name** : Atuveciclib  
**Cat. No.** : PC-60537  
**CAS No.** : 1414943-88-6  
**Molecular Formula** : C<sub>18</sub>H<sub>18</sub>FN<sub>5</sub>O<sub>2</sub>S  
**Molecular Weight** : 387.433  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable **CDK9/P-TEFb** inhibitor with IC<sub>50</sub> of 6 nM for CDK9/CyclinT1.

Atuveciclib displays >150-fold selectivity over CDK1/2/3/5/6/7 (IC<sub>50</sub>>800 nM), also shows submicromolar inhibitory activity against GSK3α (IC<sub>50</sub>=45 nM), GSK3β (IC<sub>50</sub>=87 nM).

Atuveciclib demonstrates antiproliferative activity against HeLa cells (IC<sub>50</sub>=920 nM) and MOLM-13 cells (IC<sub>50</sub>=310 nM).

Atuveciclib exhibits anticancer activity in human AML models.

## References

Lücking U, et al. *ChemMedChem*. 2017 Nov 8;12(21):1776-1793.

Narita T, et al. *Blood*. 2017 Aug 31;130(9):1114-1124.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com